Traders should monitor the March 26 earnings call for potential updates on cash runway, clinical progress, or partnerships, which could move the stock. Absent new data, this is a routine procedural announcement.
Price Chart
Executive Summary
Rani Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, followed by a conference call. The press release contains no actual financial data, guidance, or material business updates beyond the announcement of an upcoming earnings call.
Key Facts
- Rani Therapeutics will release Q4 and full-year 2025 financial results on March 26, 2026, after market close.
- Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
- No financial figures, guidance, or material operational updates were disclosed in this announcement.
- The company remains in the clinical-stage, focused on oral delivery of biologics via its RaniPill® platform.
Financial Impact
No financial impact from this release; actual results pending earnings announcement.
Risk Factors
- High cash burn typical of clinical-stage biotechs; no revenue-generating products yet.
- Risk of negative sentiment if upcoming earnings reveal delayed trials, funding concerns, or lack of partnership progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259426 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $0.8200 $0.8645 | ▲ +5.43% | ▲ +6.66% | $0.6172 (−24.73%) |
Jul 15, 2026 14w ago | Press Release | $0.6770 $0.8028 | ▲ +18.58% | ▲ +16.24% | $0.6172 (−8.83%) |
May 15, 2026 23w ago | Press Release | $0.9720 $0.7597 | ▼ −21.84% | ▼ −23.42% | $0.6172 (−36.50%) |
Mar 26, 2026 30w ago | Press Release | $0.8110 $0.8900 | ▲ +9.74% | ▼ −3.00% | $0.6172 (−23.90%) |
Mar 19, 2026 31w ago | Press Release | $1.13 $0.9740 | ▼ −13.81% | ▼ −23.12% | $0.6172 (−45.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers